SkyePharma shares dented by Flutiform delay

Shares of SkyePharma took a nasty hit this morning after the company revealed that it would need to provide more data to the FDA on its asthma drug. That move could delay an NDA on Flutiform until the second half of next year, which didn't please investors one whit. SkyPharma promised more details once it has received some additional clarification from the agency, adding that the delay would likely drive up its development costs by $6 million to $10 million dollars (it sounds much less these days when translated into £3 million to £5 million). Last spring the agency approved a new asthma treatment--Zyflo--that uses the UK company's drug delivery technology.

- read the report on SkyePharma from the International Herald Tribune

Related Articles:
SkyePharma gets long-awaited Flutiform partner. Report
Skyepharma opens books to interested suitors. Report
Zyflo flunks mid-stage study for severe acne. Report